First annual report of the Austrian CML registry
| Autor: | Stefan Schmidt, Alois Walder, Wolfgang Linkesch, Josef Thaler, Manfred Mitterer, Otto Krieger, Sonja Burgstaller, Ernst Schlögl, Günther Gastl, Hermine Agis, Andreas L. Petzer, Michael A. Fridrik, Markus Korger, Wolfgang Eisterer, Alois Lang, Ernst Wöll, Michael Pober, Peter Valent, Dominik Wolf, Tamer Sliwa |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Adolescent medicine.medical_treatment Blastic Phase Risk Assessment Young Adult Risk Factors hemic and lymphatic diseases Internal medicine Leukemia Myelogenous Chronic BCR-ABL Positive medicine Prevalence Humans Cumulative incidence Progression-free survival Registries Aged Aged 80 and over Chemotherapy business.industry Imatinib General Medicine Middle Aged medicine.disease Survival Analysis Transplantation Clinical trial Survival Rate Leukemia Austria Female business medicine.drug |
| Zdroj: | Wiener klinische Wochenschrift. 122(19-20) |
| ISSN: | 1613-7671 |
| Popis: | The Austrian chronic myeloid leukemia (CML) registry monitors individual disease courses, treatments applied, clinical outcome, and side effects of CML patients on a nationwide basis to provide data on the "real-life" situation and to complement the information and interpretation gained from the selected patient population observed in clinical trials. This report summarizes the Austrian CML registry data as of March 2009. A total of 179 patients have been registered with a median number of 1012 follow-up visits and median observation duration of 20 months. At diagnosis most patients (n = 163) were in chronic phase (early, late, and secondary), whereas only 4 were in advanced phase. A total of 137 patients were treated with tyrosine kinase inhibitors (TKIs), of which 14 received first and second generation TKIs sequentially. Other treatment modalities included chemotherapy or interferon and stem cell transplantation (SCT). Cumulative incidence rates for complete hematological responses (CHR) were 91.6% and 94.4% at 12 and 24 months, respectively, compared to cumulative incidence rates of complete cytogenetical response rates of 64% and 80% at these timepoints. A total of 5 patients progressed from chronic phase to accelerated (n = 3) and blastic phase (n = 2) while receiving imatinib standard dose. Estimated overall survival (OS) rate at 60 months was 90% and progression free survival (PFS) according to European Leukemia Net (ELN) failure definition was 58%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink